NCE-1 Intelligence & Market Opportunity

Rezurock

Belumosudil

Immunomodulators

Oral Tablet

Approval Date

16-Jul-21

NCE-1 Date

16-Jul-25

NCE Date

16-Jul-26

Commercial snapshot

Market performance & projections

Revenue ($M)

553

CAGR (%)

0.0824

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

626

2027

688

2028

737

2029

759

2030

782

2031

802

2032

824

Molecule profile

Details & specifications

Molecule

Belumosudil

Innovator

KADMON PHARMACEUTICALS, LLC

Dosage Form

Oral Tablet

Strength

EQ 200 mg base

Therapeutic Category

Immunomodulators

Usage

To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.